Abstract
Background: Alcohol has been used for centuries in many different civilizations. It is a psychoactive stimulant with addictive properties. Alcohol misuse has significant negative social, economic, and health effects. Abusing alcohol can cause harm to oneself as well as to relatives, coworkers, close companions, and total strangers. Alcohol usage contributes to more than 200 diseases, accidents, and other health problems. Drinking alcohol is associated with a higher chance of developing significant non-communicable illnesses such liver cirrhosis, a number of cancers, cardiovascular diseases, as well as behavioral and mental disorders like alcoholism.
Objective: Abuse of alcohol does not occur suddenly. People becoming addicted to various alcoholic beverages is a problem that results from months and years of irresponsible drinking. The process of recovering from the issue in turn includes targeted, particular methods for raising awareness of the negative effects of alcohol usage.
Conclusion: Due to the heightened risks for one's bodily and mental health along with the social issues it generates, alcohol consumption results in these costs. We discuss the three areas of the epidemiology of alcohol's impact on health and diseases, the public health approach for treating problems related to alcohol use, and advancements in alcohol science.
Graphical Abstract
[1]
Rehm J. The risks associated with alcohol use and alcoholism. Alcohol Res Health 2011; 34(2): 135.
[2]
Ramanan VV, Singh SK. A study on alcohol use and its related health and social problems in rural Puducherry India. J Family Med Prim Care 2016; 5(4): 804.
[3]
Ohashi K, Pimienta M, Seki E. Alcoholic liver disease: A current molecular and clinical perspective. Liver Res 2018; 2(4): 161-72.
[4]
Osna NA, Donohue TM Jr, Kharbanda K. Alcoholic liver disease: Pathogenesis and current management. Alcohol Res 2017; 38(2): 147.
[5]
Weiskirchen R, Weiskirchen S, Tacke F. Recent advances in understanding liver fibrosis: Bridging basic science and individualized treatment concepts. F1000 Res 2018; 7.
[6]
Shabeena S, Narendra JB. Case report on alcoholic hepatitis in 50 years male patient. IJARESM 2018; 9(11)
[7]
Bellentani S, Saccoccio G, Costa G, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut 1997; 41(6): 845-50.
[8]
Becker U, Deis A, Sorensen TI, Gronbaek M. Prediction of risk of liver disease by alcohol intake, sex, and age: A prospective population study. J Hepatol 1996; 23(5): 1025-9.
[9]
Patel R, Mueller M, Doerr C. Alcoholic liver disease (nursing). Treasure Island, FL: StatPearls 2023.
[10]
Di M. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011; 365(19): 1790-800.
[11]
European Association for The Study of The Liver. EASL clinical practical guidelines: Management of alcoholic liver disease. J Hepatol 2012; 57(2): 399-420.
[12]
Savolainen V, Perola M, Lalu K, Penttila A, Virtanen I, Karhunen PJ. Early perivenular fibrogenesis-precirrhotic lesions among moderate alcohol consumers and chronic alcoholics. J Hepatol 1995; 23(5): 524-31.
[13]
Grant BF, Dufour MC, Harford TC. Epidemiology of alcoholic liver disease. In: Seminars in liver disease Thieme Medical Publishers. 1988; 8: pp. 12-25.
[14]
Teli MR, Day CP, James OF, Burt AD, Bennett MK. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 1995; 346(8981): 987-90.
[16]
Jones AL. Anatomy of the normal liver. In: Hepatology A textbook of liver disease. 1990; 1: p. 3.
[17]
Aragon CM, Rogan F, Amit Z. Ethanol metabolism in rat brain homogenates by a catalase-H2O2 system. Biochem Pharmacol 1992; 44(1): 93-8.
[18]
Zakhari S, Li TK. Determinants of alcohol use and abuse: Impact of quantity and frequency patterns on liver disease. Hepatol 2007; 46(6): 2032-9.
[19]
Hock B, Schwarz M, Domke I, et al. Validity of carbohydratedeficient transferrin (% CDT), γ-glutamyltransferase (γ-GT) and mean corpuscular erythrocyte volume (MCV) as biomarkers for chronic alcohol abuse: A study in patients with alcohol dependence and liver disorders of non-alcoholic and alcoholic origin. Addiction 2005; 100(10): 1477-86.
[20]
Alatalo P, Koivisto H, Puukka K, et al. Biomarkers of liver status in heavy drinkers, moderate drinkers and abstainers. Alcohol Alcohol 2009; 44(2): 199-203.
[21]
Chrostek L, Panasiuk A. Liver fibrosis markers in alcoholic liver disease. World J Gastroenterol 2014; 20(25): 8018.
[22]
Naveau S, Gaudé G, Asnacios A, et al. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. J Hepatol 2009; 49(1): 97-105.
[23]
Castera L, Pinzani M. Biopsy and non-invasive methods for the diagnosis of liver fibrosis: Does it take two to tango. World J Gastroenterol Gut 2010; 59(7): 861-6.
[24]
Nahon P, Kettaneh A, Tengher-Barna I, Ziol M. Assessment of liver fibrosis using transient elastography in patients with alcoholic liver disease. J Hepatol 2008; 49(6): 1062-8.
[25]
Nguyen-Khac E, Saint-Leger P, Tramier B, Coevoet H, Capron D, Dupas JL. Noninvasive diagnosis of large esophageal varices by Fibroscan: Strong influence of the cirrhosis etiology. Alcohol Clin Exp Res 2010; 34(7): 1146-53.
[26]
Mueller S, Millonig G, Sarovska L, et al. Increased liver stiffness in alcoholic liver disease: Differentiating fibrosis from steatohepatitis. World J Gastroenterol 2010; 16(8): 966.
[27]
Gelsi E, Dainese R, Truchi R, et al. Effect of detoxification on liver stiffness assessed by Fibroscan® in alcoholic patients. Alcohol Clin Exp Res 2011; 35(3): 566-70.
[28]
Mathurin P, Bataller R. Trends in the management and burden of alcoholic liver disease. J Hepatol 2015; 62(1): S38-46.
[29]
d’Assignies G, Fontés G, Kauffmann C, et al. Early detection of liver steatosis by magnetic resonance imaging in rats infused with glucose and intralipid solutions and correlation to insulin levels. Metabolism 2013; 62(12): 1850-7.
[30]
Sorensen TA, Bentsen K, Eghoje K, Orholm M, Hoybye G, Offersen P. Prospective evaluation of alcohol abuse and alcoholic liver injury in men as predictors of development of cirrhosis. Lancet 1984; 324(8397): 241-4.
[31]
Addolorato G, Mirijello A, Barrio P, Gual A. Treatment of alcohol use disorders in patients with alcoholic liver disease. J Hepatol 2016; 65(3): 618-30.
[32]
Chao A, Waitzberg D. Malnutrition and nutritional support in alcoholic liver Disease: A Rev. Curr Gastroenterol Rep 2016; 18(12): 1-1.
[33]
Pavlov CS, Casazza G, Semenistaia M, et al. Ultrasonography for diagnosis of alcoholic cirrhosis in people with alcoholic liver disease. Cochrane Database of Sys Revi 2016; 3: CD011602.
[34]
Mathurin P, Duchatelle V, Ramond MJ, et al. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterol 1996; 110(6): 1847-53.
[35]
Mathurin P, Louvet A, Duhamel A, et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: A randomized clinical trial. J Am Med Assoc Jama 2013; 310(10): 1033-41.
[36]
Ramond MJ, Poynard T, Rueff B, et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 1992; 326(8): 507-12.
[37]
Taïeb J, Mathurin P, Elbim C, et al. Blood neutrophil functions and cytokine release in severe alcoholic hepatitis: Effect of corticosteroids. J Hepatol 2000; 32(4): 579-86.
[38]
Oshea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Official J Am College Gastroenterol 2010; 105(1): 14-32.
[39]
Mathurin P, O'Grady J, Carithers RL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: Meta-analysis of individual patient data. World J gastroenterolGut 2011; 60(2): 255-60.
[40]
Louvet A, Naveau S, Abdelnour M, et al. The Lille model: A new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. J Hepatol 2007; 45(6): 1348-54.
[41]
Saberi B, Dadabhai AS, Jang YY, Gurakar A, Mezey E. Current management of alcoholic hepatitis and future therapies. J Clin Transl Hepatol 2016; 4(2): 113.
[42]
Halsted CH. Nutrition and alcoholic liver disease. In: InSeminars in liver disease. New York, NY: Thieme Medical Publishers 2004.
[43]
Mendenhall C, Roselle GA, Gartside P, Moritz T. Veterans administration cooperative study groups 119 and 275. Relationship of protein calorie malnutrition to alcoholic liver disease: A reexamination of data from two veterans administration cooperative studies. Alcohol Clin Exp Res 1995; 19(3): 635-41.
[44]
Stickel F, Hoehn B, Schuppan D, Seitz HK. Nutritional therapy in alcoholic liver disease. AlimenTherap 2003; 18(4): 357-73.
[45]
Frazier TH, Stocker AM, Kershner NA, Marsano LS, McClain CJ. Treatment of alcoholic liver disease. Therap Adv Gastroenterol 2011; 4(1): 63-81.
[46]
Mohammad MK, Zhou Z, Cave M, Barve A, McClain CJ. Zinc and liver disease. Nutr Clin Pract 2012; 27(1): 8-20.
[47]
Smilkstein MJ, Bronstein AC, Linden C, Augenstein WL, Kulig KW, Rumack BH. Acetaminophen overdose: A 48-hour intravenous N-acetylcysteine treatment protocol. Ann Emerg Med 1991; 20(10): 1058-63.
[48]
Phillips M, Curtis H, Portmann B, Donaldson N, Bomford A, O’Grady J. Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis-a randomised clinical trial. J Hepatol 2006; 44(4): 784-90.
[49]
Nguyen-Khac E, Thevenot T, Piquet MA, et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med 2011; 365(19): 1781-9.
[50]
Tilg H, Jalan R, Kaser A, et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 2003; 38(4): 419-25.
[51]
Spahr L, Rubbia-Brandt L, Frossard JL, et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: A randomized controlled pilot study. J Hepatol 2002; 37(4): 448-55.
[52]
Naveau S, Chollet-Martin S, Dharancy S, et al. Foie-Alcohol group of the association française pour l’Etude du Foie (AFEF). A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. J Hepatol 2004; 39(5): 1390-7.
[53]
Thursz MR, Richardson P, Allison M, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med 2015; 372(17): 1619-28.
[54]
Kim WR, Lake JR, Smith JM, et al. OPTN/SRTR 2015 annual data report: Liver. Am J Transplant 2017; 17: 174-251.
[55]
Weeks SR, Sun Z, McCaul ME, et al. Liver transplantation for severe alcoholic hepatitis, updated lessons from the world’s largest series. J Am Coll Surg 2018; 226(4): 549-57.
[56]
Lee BP, Mehta N, Platt L, et al. Outcomes of early liver transplantation for patients with severe alcoholic hepatitis. Nat Rev Gastroenterol Hepatol 2018; 155(2): 422-30.
[57]
Lucey MR. Liver transplantation for alcoholic liver disease. Nature RevGastroenteric Hepatol 2014; 11(5): 300-7.
[58]
Singal AK, Bashar H, Anand BS, Jampana SC, Singal V, Kuo YF. Outcomes after liver transplantation for alcoholic hepatitis are similar to alcoholic cirrhosis: Exploratory analysis from the UNOS database. J Hep 2012; 55(5): 1398-405.
[59]
Singal AK, Chaha KS, Rasheed K, Anand BS. Liver transplantation in alcoholic liver disease current status and controversies. World J Gastroenterol 2013; 19(36): 5953.
[60]
Bergheim I, McClain CJ, Arteel GE. Treatment of alcoholic liver disease. Dig Dis 2005; 23(3-4): 275-84.
[61]
Donnadieu-Rigole H, Olive L, Nalpas B, et al. Follow-up of alcohol consumption after liver transplantation: Interest of an addiction team? Alcoholism: Clin Res 2017; 41(1): 165-70.
[62]
Strader DB, Bacon BR, Lindsay KL, et al. Use of complementary and alternative medicine in patients with liver disease. Am J Gastroenterol 2002; 97(9): 2391-7.
[63]
Kim MS, Ong M, Qu X. Optimal management for alcoholic liver disease: Conventional medications, natural therapy or combination? World J Gastroenterol 2016; 22(1): 8.
[64]
Kong X, Feng D, Mathews S, Gao B. Hepatoprotective and antifibrotic functions of interleukin-22: Therapeutic potential for the treatment of alcoholic liver disease. J Gastroenterol Hepatol 2013; 28: 56-60.
[65]
Ki SH, Park O, Zheng M, et al. Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: Role of signal transducer and activator of transcription 3. J Hepatol 2010; 52(4): 1291-300.
[66]
Zhang Y, Cobleigh MA, Lian JQ, et al. A proinflammatory role for interleukin-22 in the immune response to hepatitis B virus. Nat Rev Gastroenterol Hepatol 2011; 141(5): 1897-906.
[67]
Park O, Wang H, Weng H, et al. In vivo consequences of liverspecific interleukin-22 expression in mice: Implications for human liver disease progression. J Hepatol 2011; 54(1): 252-61.
[68]
Petrasek J, Bala S, Csak T, et al. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J Clin Invest 2012; 122(10): 3476-89.
[69]
Ohashi K, Pimienta M, Seki E. Alcoholic liver disease: A current molecular and clinical perspective. Liver Res 2018; 2(4): 161-72.
[70]
Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 2008; 7(8): 678-93.
[71]
Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2013; 145(3): 574-82.
[72]
Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, nonalcoholic steatohepatitis (FLINT): Amulticenter, randomized, placebo-controlled trial. Lancet 2015; 385(9972): 956-65.
[73]
Gadaleta RM, van Mil SW, Oldenburg B, Siersema PD, Klomp LW, van Erpecum KJ. Bile acids and their nuclear receptor FXR: Relevance for hepatobiliary and gastrointestinal disease. Biochimica et Biophysica Acta (BBA)-. Mol Cell Bio Lipids 2010; 1801(7): 683-92.
[74]
Hartmann P, Hochrath K, Horvath A, et al. Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice. J Hepatol 2018; 67(6): 2150-66.
[75]
Esfandiari F, Medici V, Wong DH, et al. Epigenetic regulation of hepatic endoplasmic reticulum stress pathways in the ethanol-fed cystathionine beta synthase-deficient mouse. J Hepatol 2010; 51(3): 932-41.
[76]
Lu SC, Mato JM. Role of methionine adenosyl transferase and Sadenosylmethionine in alcohol-associated liver cancer. Alcohol 2005; 35(3): 227-34.
[77]
Mato JM, Cámara J, De Paz JF, et al. S-adenosylmethionine in alcoholic liver cirrhosis: A randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999; 30(6): 1081-9.
[78]
Medici V, Virata MC, Peerson JM, et al. S-adenosyl-L-methionine treatment for alcoholic liver disease: A double-blinded, randomized, placebo-controlled trial. Alcohol Clin Exp Res 2011; 35(11): 1960-5.
[79]
Guo T, Chang L, Xiao Y, Liu Q. S-adenosyl-L-methionine for the treatment of chronic liver disease: A systematic review and metaanalysis. PLoS One 2015; 10(3): e0122124.
[80]
Patel R, Mueller M, Doerr C. Alcoholic liver disease (nursing). Treasure Island, FL: Stat Pearls 2022.
[82]
Stevens PE, Levin A. Kidney disease: Improving global outcomes chronic kidney disease guideline development work group members*. Evaluation and management of chronic kidney disease: Synopsis of the kidney disease: Improving global outcomes 2012 clinical practice guideline. Ann Intern Med 2013; 158(11): 825-30.
[83]
Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease-A systematic review and meta-analysis. PLoS One 2016; 11(7): e0158765.
[84]
Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. J the Ame Med Ass Jama 2007; 298(17): 2038-47.
[85]
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351(13): 1296-305.
[86]
Levin A, Stevens PE, Bilous RW, et al. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3(1): 1-50.
[87]
Shankar A, Klein R, Klein BE. The association among smoking, heavy drinking, and chronic kidney disease. Am J Epidemiol 2006; 164(3): 263-71.
[88]
Perneger TV, Whelton PK, Puddey IB, Klag MJ. Risk of end-stage renal disease associated with alcohol consumption. Am J Epidemiol 1999; 150(12): 1275-81.
[89]
White SL, Dunstan DW, Polkinghorne KR, Atkins RC, Cass A, Chadban SJ. Physical inactivity and chronic kidney disease in Australian adults: The AusDiab study. Nutr Metab Cardiovasc Dis 2011; 21(2): 104-12.
[90]
Weinstein JR, Anderson S. The aging kidney: Physiological changes. Adv Chronic Kidney Dis 2010; 17(4): 302-7.
[91]
Bundy JD, Bazzano LA, Xie D, et al. Self-reported tobacco, alcohol, and illicit drug use and progression of chronic kidney disease. Clin J Am Soc Nephrol 2018; 13(7): 993-1001.
[92]
Chen J, Kong X, Jia X, et al. Association between metabolic syndrome and chronic kidney disease in a Chinese urban population. Clin Chim Acta 2017; 470: 103-8.
[93]
Hsu YH, Pai HC, Chang YM, Liu WH, Hsu CC. Alcohol consumption is inversely associated with stage 3 chronic kidney disease in middle-aged Taiwanese men. BioMed Central BMC Nephrol 2013; 14(1): 1-9.
[94]
Shimizu Y, Maeda K, Imano H, et al. Chronic kidney disease and drinking status in relation to risks of stroke and its subtypes: The Circulatory Risk in Communities Study (CIRCS). Stroke 2011; 42(9): 2531-7.
[95]
Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: A review. J Amer Med AssJama 2019; 322(13): 1294-304.
[96]
Miller WG. National kidney disease education program-IFCC working group on standardization of albumin in urine, current issues in measurement and reporting of urinary albumin excretion. Clin Chem 2009; 55(1): 24-38.
[97]
Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. J Ame Medical AssoJama 2003; 289(19): 2560-71.
[98]
James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee. J Ame Medical Asso Jama 2014; 311(5): 507-20.
[99]
Taler SJ, Agarwal R, Bakris GL, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am J Kidney Dis 2013; 62(2): 201-13.
[100]
Sebastian RS, Enns CW, Goldman JD, Hoy MK, Moshfegh AJ. Sandwiches are major contributors of sodium in the diets of American adults: Results from what we eat in america, national health and nutrition examination survey 2009-2010. J Acad Nutr Diet 2015; 115(2): 272-7.
[101]
Kidney Disease: Improving Global Outcomes (KDIGO) CKDMBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; 76(113): S1-S130.
[102]
Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369(20): 1892-903.
[103]
Yusuf S, Pogue J, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358(15): 1547-59.
[104]
Vassalotti JA, Centor R, Turner BJ, Greer RC, Choi M, Sequist TD. National kidney foundation kidney disease outcomes quality initiative. Practical approach to detection and management of chronic kidney disease for the primary care clinician. Am J Med 2016; 129(2): 153-62.
[105]
Wagener HP, Keith NM. Diffuse arteriolar disease with hypertension and the associated retinal lesions. Med 1939; 18(3): 317-430.
[106]
Graves JW. Diagnosis and management of chronic kidney disease. Mayo Clin Proc 2008; 83: 1064-9.
[107]
Howard AD, Moore J Jr, Gouge SF, et al. Routine serologic tests in the differential diagnosis of the adult nephrotic syndrome. Ame Kidney Dis 1990; 15(1): 24-30.
[108]
Hollenberg NK. Treatment of the patient with diabetes mellitus and risk of nephropathy: what do we know, and what do we need to learn? Arch Int Med 2004; 164(2): 125-30.
[109]
Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: A meta-analysis. J Am Soc Nephrol 2006; 17(7): 2006-16.
[110]
Matsumoto C, Miedema MD, Ofman P, Gaziano JM, Sesso HD. An expanding knowledge of the mechanisms and effects of alcohol consumption on cardiovascular disease. J Cardiopulm Rehabil Prev 2014; 34(3): 159-71.
[111]
Gaziano JM, Hennekens CH, Godfried SL, et al. Type of alcoholic beverage and risk of myocardial infarction. Am J Cardiol 1999; 83(1): 52-7.
[112]
Keil U, Chambless LE, Döring A, Filipiak B, Stieber J. The relation of alcohol intake to coronary heart disease and all-cause mortality in a beer-drinking population. Epidemiology 1997; 8(2): 150-6.
[113]
Hammar N, Romelsjö A, Alfredsson L. Alcohol consumption, drinking pattern and acute myocardial infarction. A case referent study based on the Swedish Twin Register. J Intern Med 1997; 241(2): 125-31.
[114]
Camargo CA Jr, Stampfer MJ, Glynn RJ, et al. Moderate alcohol consumption and risk for angina pectoris or myocardial infarction in US male physicians. Ann Intern Med 1997; 126(5): 372-5.
[115]
Reynolds K, Lewis B, Nolen JD, Kinney GL, Sathya B, He J. Alcohol consumption and risk of stroke: A meta-analysis. JAMA 2003; 289(5): 579-88.
[116]
Feigin VL, Rinkel GJ, Lawes CM, Algra A, Bennett DA. Risk factors for subarachnoid hemorrhage: An updated systematic review of epidemiological studies. Stroke 2005; 36(12): 2773-80.
[117]
Berger K, Ajani UA, Kase CS, et al. Light-to-moderate alcohol consumption and the risk of stroke among US male physicians. N Engl J Med 1999; 341(21): 1557-64.
[118]
Sacco RL, Elkind M, Boden-Albala B, et al. The protective effect of moderate alcohol consumption on ischemic stroke. JAMA 1999; 281(1): 53-60.
[119]
Djoussé L, Levy D, Murabito JM, Cupples LA, Ellison RC. Alcohol consumption and risk of intermittent claudication in the framingham heart study. Health Study ICirculation 2000; 102(25): 3092-7.
[120]
Camargo CA, Stampfer MJ, Glynn RJ, et al. Prospective study of moderate alcohol consumption and risk of peripheral arterial disease in US male physicians. Health Study I Circulation 1997; 95(3): 577-80.
[121]
Ciccarone E. Investigators. A high-score Mediterranean dietary pattern is associated with a reduced risk of peripheral arterial disease in Italian patients with type 2 diabetes. J Thromb Haemost 2003; 1(8): 1744-52.
[122]
Beulens JW, Algra A, Soedamah-Muthu SS, Visseren FL, Grobbee DE, Van der Graaf Y. Alcohol consumption and risk of recurrent cardiovascular events and mortality in patients with clinically manifest vascular disease and diabetes mellitus: The Second Manifestations of ARTerial (SMART) disease study. Atherosclerosis 2010; 212(1): 281-6.
[124]
Segel LD, Klausner SC, Gnadt JT, Amsterdam EA. Alcohol and the heart. Med Clin North Am 1984; 68(1): 147-61.
[125]
Cooper HA, Exner DV, Domanski MJ. Light-to-moderate alcohol consumption and prognosis in patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000; 35(7): 1753-9.
[126]
Walsh CR, Larson MG, Evans JC, et al. Alcohol consumption and risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med 2002; 136(3): 181-91.
[127]
Bryson CL, Mukamal KJ, Mittleman MA, et al. The association of alcohol consumption and incident heart failure: The cardiovascular health study. J Am Coll Cardiol 2006; 48(2): 305-11.
[128]
Djoussé L, Gaziano JM. Alcohol consumption and risk of heart failure in the Physicians’ Health Study I. Circulation 2007; 115(1): 34-9.
[129]
Greenspon AJ, Schaal SF. The” holiday heart”: Electrophysiologic studies of alcohol effects in alcoholics. Ann Intern Med 1983; 98(2): 135-9.
[130]
Rich EC, Siebold C, Campion B. Alcohol-related acute atrial fibrillation: A case-control study and review of 40 patients. Arch Intern Med 1985; 145(5): 830-3.
[131]
Frost L, Vestergaard P. Alcohol and risk of atrial fibrillation or flutter: A cohort study. Arch Intern Med 2004; 164(18): 1993-8.
[132]
Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997; 96(7): 2455-61.
[133]
Djoussé L, Levy D, Benjamin EJ, et al. Long-term alcohol consumption and the risk of atrial fibrillation in the Framingham Study. Am J Cardiol 2004; 93(6): 710-3.
[134]
Mukamal KJ, Tolstrup JS, Friberg J, Jensen G, Grønbaek M. Alcohol consumption and risk of atrial fibrillation in men and women: The Copenhagen City Heart Study. Circulation 2005; 112(12): 1736-42.
[135]
Klatsky AL. Alcohol, cardiovascular diseases and diabetes mellitus. Pharmacol Res 2007; 55(3): 237-47.
[139]
Reynolds ES. An account of the epidemic outbreak of arsenical poisoning occurring in beer drinkers in the north of England and the midland counties in 1900. Med Chir Trans 1901; 84: 409.
[140]
Newcomer JW, Hennekens CH. Severe mental illness and risk of cardiovasculardisease. J Ame Med Asso Jama 2007; 298(15): 1794-6.
[141]
Blacket RB, Palmer AJ. Haemodynamic studies in high output beri-beri. Br Heart J 1960; 22(4): 483.
[142]
Fernández-Solà J, Nicolás JM, Oriola J, et al. Angiotensinconverting enzyme gene polymorphism is associated with vulnerability to alcoholic cardiomyopathy. Ann Intern Med 2002; 137(5_Part_1): 321-6.
[143]
Pasotti M, Repetto A, Tavazzi L, Arbustini E. Genetic predisposition to heart failure. Med Clin 2004; 88(5): 1173-92.
[144]
Lian C. Alcoholism, cause hypertension arterielle. Bulltin Academy Nat Med Paris 1915; 7: 525-8.
[145]
Klatsky AL. Alcohol and hypertension: Does it matter? Yes. J Cardiovasc Risk 2003; 10(1): 21-4.
[146]
Mohler ER, Townsend RR, Eds. Advanced therapy in hypertension and vascular disease. USA: operation for the People’ s Medical Publishing House. 2006.
[147]
Friedman K, Siegelaub GD. Alcohol consumption among white. black or oriental men and women: Kaiser-Permanente multiphnsic health examination data. Am J Epid 1977; 105(31): l-323.
[148]
Klatsky AL, Friedman GD, Armstrong MA. The relationships between alcoholic beverage use and other traits to blood pressure: A new Kaiser Permanente study. Circulation 1986; 73(4): 628-36.
[149]
Beilin LJ, Puddey IB. Alcohol, hypertension and cardiovascular disease implications for management. Clin Exp Hypertens 1993; 15(6): 1157-70.
[150]
Puddey IB, Beilin LJ, Vandongen R. Regular alcohol use raises blood pressure in treated hypertensive subjects: A randomized controlled trial. Lancet 1987; 1: 647-51.
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Cancer Drug Targets
Combinatorial Chemistry & High Throughput Screening
Current Cancer Therapy Reviews
Current Diabetes Reviews
Current Drug Safety
Current Drug Targets
Current Drug Metabolism
Related Books
Anthocyanins: Pharmacology and Nutraceutical Importance
The Roles and Responsibilities of Clinical Pharmacists in Hospital Settings
Bioactive Compounds from Medicinal Plants for Cancer Therapy and Chemoprevention
Drug Addiction Mechanisms in the Brain
Software and Programming Tools in Pharmaceutical Research
Objective Pharmaceutics: A Comprehensive Compilation of Questions and Answers for Pharmaceutics Exam Prep
Medicinal Chemistry of Drugs Affecting Cardiovascular and Endocrine Systems
Advanced Pharmacy
Plant-derived Hepatoprotective Drugs
The Role of Chromenes in Drug Discovery and Development
